Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $537.10 | 7 | 45.8% |
| Grant | $437.11 | 1 | 37.3% |
| Education | $198.95 | 2 | 17.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $437.11 | 1 | $0 (2020) |
| Seattle Genetics, Inc. | $189.41 | 2 | $0 (2019) |
| Foundation Medicine, Inc. | $154.65 | 2 | $0 (2018) |
| Genentech USA, Inc. | $141.55 | 1 | $0 (2019) |
| GENZYME CORPORATION | $113.92 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $99.00 | 1 | $0 (2020) |
| Daiichi Sankyo Inc. | $22.33 | 1 | $0 (2024) |
| Amgen Inc. | $15.19 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22.33 | 1 | Daiichi Sankyo Inc. ($22.33) |
| 2023 | $15.19 | 1 | Amgen Inc. ($15.19) |
| 2020 | $536.11 | 2 | Novo Nordisk Inc ($437.11) |
| 2019 | $444.88 | 4 | Seattle Genetics, Inc. ($189.41) |
| 2018 | $154.65 | 2 | Foundation Medicine, Inc. ($154.65) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2023 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 01/22/2020 | Novo Nordisk Inc | — | Grant | Cash or cash equivalent | $437.11 | General |
| 12/12/2019 | Seattle Genetics, Inc. | — | Education | In-kind items and services | $99.95 | General |
| 12/09/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $89.46 | General |
| 10/16/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $113.92 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | Genentech USA, Inc. | Herceptin (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $141.55 | General |
| Category: BioOncology | ||||||
| 11/07/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $82.07 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $72.58 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 622 | 989 | $129,523 | $75,077 |
| 2022 | 8 | 344 | 612 | $85,808 | $52,689 |
| 2021 | 1 | 14 | 19 | $2,432 | $1,946 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 138 | 265 | $33,515 | $18,374 | 54.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 89 | 155 | $27,223 | $16,412 | 60.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 116 | 206 | $18,309 | $8,909 | 48.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 68 | $12,148 | $7,303 | 60.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 91 | $11,656 | $6,747 | 57.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 30 | 30 | $6,428 | $3,923 | 61.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 31 | 31 | $5,319 | $3,124 | 58.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 52 | $4,353 | $3,070 | 70.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 27 | $3,580 | $2,661 | 74.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 39 | $3,528 | $1,836 | 52.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $1,851 | $1,451 | 78.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 14 | $1,616 | $1,267 | 78.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 86 | 254 | $32,337 | $18,731 | 57.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 63 | 99 | $17,654 | $10,826 | 61.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 50 | 50 | $10,987 | $6,463 | 58.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 62 | $6,155 | $4,861 | 79.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 44 | 57 | $5,118 | $2,880 | 56.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $3,260 | $2,559 | 78.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 22 | $4,013 | $2,463 | 61.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 24 | $3,184 | $1,788 | 56.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 13 | 13 | $2,135 | $1,350 | 63.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 14 | $966.42 | $770.33 | 79.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 19 | $2,432 | $1,946 | 80.0% |
About Dr. Ryan Vaca, M.D
Dr. Ryan Vaca, M.D is a Hematology & Oncology healthcare provider based in Sioux Falls, South Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2013. The National Provider Identifier (NPI) number assigned to this provider is 1700222148.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Vaca, M.D has received a total of $1,173 in payments from pharmaceutical and medical device companies, with $22.33 received in 2024. These payments were reported across 10 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($537.10).
As a Medicare-enrolled provider, Vaca has provided services to 980 Medicare beneficiaries, totaling 1,620 services with total Medicare billing of $129,712. Data is available for 3 years (2021–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Student in an Organized Health Care Education/Training Program
- Location Sioux Falls, SD
- Active Since 05/13/2013
- Last Updated 09/01/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700222148
Products in Payments
- FOUNDATIONONE (Device) $154.65
- Herceptin (Biological) $141.55
- JEVTANA (Drug) $113.92
- Enhertu (Drug) $22.33
- Vectibix (Biological) $15.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sioux Falls
Kelly Mccaul, M.d, M.D
Hematology & Oncology — Payments: $1.5M
Dr. Brian Leyland-Jones, M.d, M.D
Hematology & Oncology — Payments: $596,161
Benjamin Solomon, Md, MD
Hematology & Oncology — Payments: $7,096
Miroslaw Mazurczak, M.d, M.D
Hematology & Oncology — Payments: $2,793
Mark Huber, M.d, M.D
Hematology & Oncology — Payments: $1,305
Dr. Houman Nourkeyhani, M.d, M.D
Hematology & Oncology — Payments: $794.82